Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top line but beat significantly on profitability: revenue of $119.2M vs. $121.0M expected, while GAAP EPS reached $1.79, exceeding the $1.63 mean estimate. Strong gross margins of 95.0% (in-line) and efficient manufacturing helped drive an EBIT of $58.4M, 6.38% above consensus. While U.S. sales declined, international launches in Europe and Japan provided a critical growth offset, contributing $27.6M to the quarter.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Krystal Biotech(KRYS) the Revenue is 119.22 M (+24.14%), Miss estimate;the EBIT is 58.42 M (+48.62%), Beat estimate;the EPS is 1.79 (+38.76%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.12B24.14%
0.12B26.03%
-0.00B1.89%
EBITExceed expectations
0.06B48.62%
0.05B39.70%
+0.00B8.92%
EPSExceed expectations
1.7938.76%
1.627526.16%
+0.162512.60%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf